Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

Blood

Volumn 119, Issue 6, 2012, Pages 1599-1606

  Schmid, Christoph ^a   Labopin, Myriam ^b   Nagler, Arnon ^c   Niederwieser, Dietger ^d   Castagna, Luca ^e   Tabrizi, Reza ^f   Stadler, Michael ^g   Kuball, Jürgen ^h   Cornelissen, Jan ⁱ   Vorlicek, Jiri ^j   Socié, Gerard ^k   Falda, Michele ^l   Vindeløv, Lars ^m   Ljungman, Per ⁿ   Jackson, Graham ^o   Kröger, Nicolaus ^p   Rank, Andreas ^a   Polge, Emmanuelle ^b   Rocha, Vanderson ^k   Mohty, Mohamad ^q  

^a UNIVERSITY OF MUNICH   (Germany)

^b SORBONNE UNIVERSITÉ   (France)

^c SHEBA MEDICAL CENTER   (Israel)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e INSTITUT PAOLI CALMETTES   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^k SAINT LOUIS HOSPITAL   (France)

^l MOLINETTE HOSPITAL   (Italy)

^m Rigshospitalet   (Denmark)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o ROYAL VICTORIA INFIRMARY   (United Kingdom)

^p UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^q UNIVERSITÉ DE NANTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; AZACITIDINE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; METHOTREXATE; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER INCIDENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CYTOREDUCTIVE SURGERY; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LONG TERM SURVIVAL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT RESPONSE;

EID: 84856857935     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-375840     Document Type: Article

References (46)

1. Storb R, Champlin R, Ridell S, Mukata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. Hematology. 2001;375-391.
2. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531-4536. (Pubitemid 27260263)
3. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756-763. (Pubitemid 28078275)
4. Khouri IF, Keating M, Korbling M, et al. Transplant- lite: induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;98(13):2817-2824. (Pubitemid 28363047)
5. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94(9):3234-3241. (Pubitemid 29512733)
6. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versuslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999;353(9166):1755-1759. (Pubitemid 29240375)
7. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97(3): 631-637. (Pubitemid 32113394)
8. Nagler A, Aker M, Or R, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol. 2001;29(3):362-370. (Pubitemid 32223461)
9. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versustumor effects. Blood. 2001;97(11):3390-3400.
10. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99(3):1071-1078. (Pubitemid 34525573)
11. Niederwieser D, Maris M, Shizuru JA, et al. Lowdose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101(4):1620-1629. (Pubitemid 36182543)
12. Baldomero H, Gratwohl M, Gratwohl A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant. 2011;46(4): 485-501.
13. Aoudjhane M, Labopin M, Gorin N, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukaemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;29;19(12):2304-2312.
14. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005; 105(4):1810-1814. (Pubitemid 40223707)
15. Shimoni. A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced- intensity conditioning: the role of dose intensity. Leukemia. 2006;20(2):322-328.
16. Martino R, Iacobelli S, Brand R. Retrospective comparison of reduced intensity conditioning and conventional high dose conditioning for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood. 2006;108(3):836-846. (Pubitemid 44154615)
17. van den Brink MR, Porter DL, Giralt S, et al. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant. 2010;1(suppl): S138-S145.
18. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reducedintensity conditioning regimen has the capacity to produce durable remissions and long-term disease- free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23(36):9387-9393.
19. Al-Ali H, Cross M, Lange T, Freund M, Dolken G, Niederwieser D. Low-dose total body irradiationbased regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia. Curr Opin Oncol. 2009;(suppl 1):S17-S22.
20. Pollyea DA, Artz AS, Stock W, et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007;40(11):1027-1032. (Pubitemid 350142554)
21. Oran B, Giralt S, Couriel D, et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia. 2007;21(12): 2540-2544. (Pubitemid 350148900)
22. European Group for Blood and Marrow Transplantation. http://www.ebmt.org/ Contents/ Data-Management/Registrystructure/MEDABdatacollectionforms/Documents/ MED-ABFormsManual. pdf, page 160. Accessed August 18, 2011.
23. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol. 2002;20(2):405-412. (Pubitemid 34072522)
24. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK. Treatment of relapsed acute myeloid leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant. 2007;13(1):116-123. (Pubitemid 46044096)
25. Shaw BE, Russell NH. Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant. 2008;41(5):495-503. (Pubitemid 351386714)
26. Cheson B, Benet JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnostics, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24): 4642-4649. (Pubitemid 46594039)
27. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-4083.
28. Sullivan KM. Graft-versus-host-disease. In: Thomas E, Blume K, Forman SJ, eds. Hematopoietic Cell Transplantation (2nd Ed). Boston, MA: Blackwell Science; 1999:515-526.
29. Gooley TA, Leisenring W, Cullis JO, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
30. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-418.
31. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-202.
32. Porter DL, Alyea EP, Antin JH, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010;16(11): 1467-1503.
33. Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2001;19(16):3675-3684. (Pubitemid 32786280)
34. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem cell transplantation in adults with acute myeloid leukaemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25(31): 4938-4945. (Pubitemid 350225492)
35. Kedmi M, Resnick IB, Dray L, et al. A retrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant. 2009;15(4):483-489.
36. Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant. 2009; 44(12):769-777.
37. Mortimer J, Blinder MA, Schulman S, et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol. 1989;7(1):50-57. (Pubitemid 19089081)
38. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86(5):2041-2050.
39. Eapen M, Giralt SA, Horowitz MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004;34(8):721-727. (Pubitemid 39406056)
40. Alyea EP, DeAngelo DJ, Moldrem J, et al. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010;16(8):1037-1069.
41. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15(12):1628-1633.
42. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675-5687.
43. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacytidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009;115(9): 1899-1905.
44. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116(23):5420-5431.
45. Kröger N, Bacher U, Bader P, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse Following Allogeneic Stem Cell Transplantation: I. Methods, Acute Leukemias, and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2010;16: 1187-1211.
46. Bornhäuser M, Oelschlaegel U, Platzbecker U, et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica. 2009; 94(11):1613-1617.